CClinicalTrials.gg
CompletedNCT01802710Updated Jun 21, 2019Results posted

Clinical Improvement and in Quality of Life-Functional Dyspepsia-

An interventional study of Psychological support and No intervention in Psychogenic Dyspepsia, sponsored by Hospital Galdakao-Usansolo. Completed at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-06-21.

Sponsored by Hospital Galdakao-Usansolo · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Functional dyspepsia (FD)is defined as the presence of symptoms thought to originate in the gastroduodenal region with no evidence of structural disease that is likely to explain the symptoms. The cause of this condition is unclear, not being a recognized treatment for it. The conventional treatments for those patients are symptom based. Unfortunately, these medications are not very effective. Patients with FD report poorer health status, mental health, and social functioning than patients with structural gastrointestinal pathology. Our aim is to compare a combined intervention (medical plus psychological intervention) versus conventional intervention (medical intervention)in regard to the health related quality of life, symptomatology, anxiety and depression of those patients. The investigators hypothesized that compared with conventional intervention a combined intervention would yield significantly better short (after treatment) and medium term (six months after treatment) improvement of health related quality of life and symptoms.

Read the detailed description

Patients were recruited from the digestive services of Galdakao-Usansolo and Basurto hospitals. They were randomly allocated to the control or experimental group. 82 patients were included in the control group and 76 in the experimental group.

Regarding the intervention, the treatment of the control group was a conventional (medical) intervention. It was focused on the most bothersome symptom. Prokinetic (for example cinitapride) or antisecretory agent (for example omeprazole) was prescribed in standard dose. Experimental group received the combined intervention (medical plus psychological intervention). The psychological support consisted of ten weekly sessions, which the first 8 were in group and the last 2 were individuals. In those sessions the patients received a) an information session to increase the patients' knowledge of functional dyspepsia; b) a Beck's cognitive-behavioural therapy focused on modifying the influence of some cognitive issues to gastrointestinal symptoms; c) and progressive-muscle relaxation according to Jacobson, with the aim to provide the ability to relax in certain stress situations. This technique was created for reducing anxiety by alternately tensing and relaxing the muscles.

All the patients completed all the self questionnaires at baseline (t0), at the end of the treatment (T1) and at six months follow up (T2). The health related quality of life was assessed by the Dyspepsia Related Health Scale (DRHS), and anxiety and depression were assessed by the Hospital Anxiety and Depression Scale (HADS). Finally, the subjective clinical improvement was also considered and it was measured by a question about how they feel in regard to the functional dyspepsia, with five alternatively responses (a) Much better, b) quite a lot better, c) somewhat better, d) about the same, e) somewhat worse, f) quite a lot worse, g) much worse).

02

Conditions studied

  • Psychogenic Dyspepsia

Browse trials for

03

In context

Dyspepsia

363 studies on the registry are indexed under Dyspepsia; 51 are open to participants now.

This study's enrollment of 158 is above the median of 87 across 297 interventional studies indexed under Dyspepsia.

Browse Dyspepsia studies →

Lead sponsor

Hospital Galdakao-Usansolo is the lead sponsor of 29 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • to have chronic upper abdominal symptoms consistent with ROME III criteria for functional dyspepsia
  • to have an endoscopy to exclude structural organic causes at the time of the recruitment

Exclusion criteria

Exclusion Criteria:

  • to have any organic pathology that could explain the dyspeptic symptoms
  • to be using non-steroidal anti-inflammatory drugs (NSAIDs)
  • to suffer physical or psychological impairments preventing them from properly completing the questionnaires
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Psychological support

    Ten weekly sessions, which the first 8 were in group and the last 2 were individuals. It consists on a) an informational session; b) Beck's cognitive-behavioural therapy; and c) progressive-muscle relaxation according to Jacobson

    Behavioral: Psychological support

  • Active comparator
    No psychological support

    Patients of this group only received the conventional medical treatment, not receiving any psychological support

    Other: No intervention

Interventions

  • BehavioralPsychological support
  • OtherNo intervention
06

What researchers measure

Primary outcomes

  1. Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS)

    The Dyspepsia Related Health Scale (DRHS) is a self-reported dyspepsia-specific questionnaire that consists of four scales: severity of common symptoms, pain intensity, pain disability, and satisfaction with dyspepsia-related health. The score, for each scale, ranges between 0 and 100, with 0 representing the most severe situation and 100 the least severe. It also yields a global score that ranges from 0 to 100, with higher scores indicating less severe dyspepsia. The adapted and validated Spanish version of this questionnaire is known as QoL-PEI (Quality of Life in relation to Stomach and Intestinal Problems Questionnaire). Its reliability was found to be satisfactory (Cronbach's alpha 0.92). Its factorial analysis confirmed the four scales found by the DRHS but added a global score scale. The convergent validity was moderate (0.54).

    Time frame: Participants will be followed at the recruit moment (t0) after treatment (t1) and six months after treatment (t2)

Secondary outcomes

  1. Subjective Clinical Improvement

    Subjective clinical improvement was measured by a question about how patients feel in regard to the functional dyspepsia ("In relation to functional dyspepsia, how would you rate your health now? a)much better; b) quite a lot better; c) somewhat better; d) about the same; e) somewhat worse; f) quite a lot worse; g) much worse

    Time frame: Subjective clinical improvement it is measured after treatment (t1) and six months after treatment (t2)

Other outcomes

  1. Hospital Anxiety and Depression Scale

    It is a 14-item measure: 7 items evaluate depression (the HADS-D subscale) and 7 evaluate anxiety (the HADS-A subscale). For each subscale items range from 0 to 21. A subscale score of 0-7 indicates the absence of anxiety or depression; a score of 8-10 indicates a possible case of anxiety or depression; and a score of 11 or higher indicates the presence of anxiety or depression. It has been adapted and validated in a Spanish population

    Time frame: Participants will be followed at the recruit moment (t0) after treatment (t1) and six months after treatment (t2)

07

Results

Posted Jun 21, 2019

Participant flow

From T0 to T1
Participant flow — From T0 to T1
MilestonePsychological SupportNo Psychological Support
Started7682
Completed6072
Not completed1610
From T1 to T2
Participant flow — From T1 to T2
MilestonePsychological SupportNo Psychological Support
Started6072
Completed5870
Not completed22

Outcome measures

PrimaryChange From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS)

The Dyspepsia Related Health Scale (DRHS) is a self-reported dyspepsia-specific questionnaire that consists of four scales: severity of common symptoms, pain intensity, pain disability, and satisfaction with dyspepsia-related health. The score, for each scale, ranges between 0 and 100, with 0 representing the most severe situation and 100 the least severe. It also yields a global score that ranges from 0 to 100, with higher scores indicating less severe dyspepsia. The adapted and validated Spanish version of this questionnaire is known as QoL-PEI (Quality of Life in relation to Stomach and Intestinal Problems Questionnaire). Its reliability was found to be satisfactory (Cronbach's alpha 0.92). Its factorial analysis confirmed the four scales found by the DRHS but added a global score scale. The convergent validity was moderate (0.54).

Time frame:
Participants will be followed at the recruit moment (t0) after treatment (t1) and six months after treatment (t2)
Reported as:
Mean · units on a scale
Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS)
units on a scalePsychological SupportNo Psychological Support
Change from t0 to t1 in DRHS-severity symptoms73.72 ± 16.7665.31 ± 17.60
Change from t0 to t2 in DRHS-severity symptoms71.85 ± 20.4664.89 ± 19.22
SecondarySubjective Clinical Improvement

Subjective clinical improvement was measured by a question about how patients feel in regard to the functional dyspepsia ("In relation to functional dyspepsia, how would you rate your health now? a)much better; b) quite a lot better; c) somewhat better; d) about the same; e) somewhat worse; f) quite a lot worse; g) much worse

Time frame:
Subjective clinical improvement it is measured after treatment (t1) and six months after treatment (t2)
Reported as:
Count of participants · Participants
Subjective Clinical Improvement
ParticipantsPsychological SupportNo Psychological Support
Better in relation to functional dyspepsia at T13717
Better in relation to functional dyspepsia at T23626
Other pre-specifiedHospital Anxiety and Depression Scale

It is a 14-item measure: 7 items evaluate depression (the HADS-D subscale) and 7 evaluate anxiety (the HADS-A subscale). For each subscale items range from 0 to 21. A subscale score of 0-7 indicates the absence of anxiety or depression; a score of 8-10 indicates a possible case of anxiety or depression; and a score of 11 or higher indicates the presence of anxiety or depression. It has been adapted and validated in a Spanish population

Time frame:
Participants will be followed at the recruit moment (t0) after treatment (t1) and six months after treatment (t2)
Reported as:
Mean · units on a scale
Hospital Anxiety and Depression Scale
units on a scalePsychological SupportNo Psychological Support
Change From t0 to t1 in HADS-D8.95 ± 1.959.31 ± 2.00
From t0 to t2in HADS-D9.09 ± 1.889.71 ± 2.01

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Psychological Support———
No Psychological Support———

Baseline characteristics

In certain analyzes we lose some subjects, for example when studying Subjective Clinical Improvement (here we have 60 patients in the experimental group and 69 in the control group)

Age, Continuous
Age, Continuous(years)Psychological SupportNo Psychological SupportTotal
Mean44.28 ± 14.0647.09 ± 15.1945.73 ± 14.67
Sex: Female, Male
Sex: Female, Male(Participants)Psychological SupportNo Psychological SupportTotal
Female6466130
Male121628
Region of Enrollment
Region of Enrollment(participants)Psychological SupportNo Psychological SupportTotal
Spain7682158
08

Study locations

1 site
  • Galdakao-Usansolo Hospital
    Usansolo, Bizkaia 48960, Spain
09

References and documents

Publications

  • Orive M, Barrio I, Orive VM, Matellanes B, Padierna JA, Cabriada J, Orive A, Escobar A, Quintana JM. A randomized controlled trial of a 10 week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia. J Psychosom Res. 2015 Jun;78(6):563-8. doi: 10.1016/j.jpsychores.2015.03.003. Epub 2015 Mar 11. PubMed 25791668 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01802710
Lead sponsor
Hospital Galdakao-Usansolo
Responsible party
Miren Orive Calzada (Msc, Hospital Galdakao-Usansolo) — Principal investigator
First posted
Mar 1, 2013
Start date
Mar 2009
Primary completion
Sep 2012
Completion
Dec 2012
Results posted
Jun 21, 2019
Last update
Jun 21, 2019

Study contacts

Victor Manuel Orive, Doctor
principal investigator · Basurto University Hospital
Jose Luis Cabriada, Doctor
study chair · Hospital Galdakao-Usansolo
Aitor Orive, Doctor
study chair · Hospital Galdakao-Usansolo
Begoña Matellanes, Psychology
study chair · University of Deusto
Maria Josefa Ulloa, Nurse
study chair · Basurto University Hospital
Jesus Angel Padierna, Doctor
study chair · Hospital Galdakao-Usansolo
Antonio Escobar, Doctor
study chair · Basurto University Hospital
Antonio Bernal, Doctor
study chair · Hospital Galdakao-Usansolo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion